New hope for rare muscle disease: baricitinib trial aims to cut steroid use

NCT ID NCT04972760

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether baricitinib, a JAK inhibitor pill, can improve symptoms of dermatomyositis (a rare autoimmune disease causing muscle weakness and skin rashes) while allowing patients to stop steroids. 62 adults with active disease will receive baricitinib or a placebo for 24 weeks, alongside standard care. The goal is to see if more patients achieve moderate improvement without needing prednisone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Baricitinib (a JAK inhibitor drug taken orally)
What this could lead to: If successful, baricitinib could offer a faster, more effective treatment for dermatomyositis, reducing the need for high-dose steroids and their side effects.
What could go wrong: This is a relatively small Phase 3 trial (62 people), and baricitinib may not prove more effective than placebo. Potential risks include infections and blood clots, as seen with other JAK inhibitors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dermatomyositis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DERMATOMYOSITIS

Contacts and locations

Locations

Pitie-Salpêtrière hospital APHP
RECRUITING

Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.